Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
327 studies found for:    biogen | biogen
Show Display Options
Download search resultsDownload the search results for:
biogen | biogen (327 records)
Download Content:
Zip file readers with free trial periods: WinZip or PKZip
Rank Status Study
1 Terminated Assessment of the Safety and Efficacy of BG9924 in Rheumatoid Arthritis (RA) Patients
Condition: Rheumatoid Arthritis
Intervention: Biological: Baminercept alfa (BG9924)
2 Completed Open-Label Safety Extension Study of Avonex
Condition: Multiple Sclerosis
Intervention: Drug: Interferon beta-1a (Avonex)
3 Recruiting A Healthy Volunteer Study to Establish the Bioequivalence of BG00012 Supplied by 2 Different Commercial Manufacturers
Condition: Healthy
Interventions: Drug: BG00012 (dimethyl fumarate) - Reference form;   Drug: BG00012 (dimethyl fumarate) - Test form
4 Terminated BG9924 in Combination With Methotrexate Extension of Study 104RA203
Condition: Rheumatoid Arthritis
Intervention: Drug: BG9924
5 Recruiting TOP: IMA-06-02 Tysabri® Observational Program
Condition: Relapsing-Remitting Multiple Sclerosis
Intervention:
6 Recruiting An Open Label Study to Determine the Safety and Efficacy of Replacement Factor IX Protein (Known as rFIXFc) in Untreated Males With Severe Hemophilia B
Condition: Hemophilia B
Intervention: Biological: BIIB029 (rFIXFc)
7 Recruiting BIIB023 Proof-of-Concept Study in Participants With Lupus Nephritis
Condition: Lupus Nephritis
Interventions: Biological: BIIB023;   Biological: Placebo;   Drug: Mycophenolate Mofetil;   Drug: Oral corticosteroid regimen
8 Not yet recruiting An Open Label Study to Determine the Safety and Efficacy of Replacement Factor VIII Protein (Known as rFVIIIFc) in Untreated Males With Severe Hemophilia A
Condition: Hemophilia A
Intervention: Biological: BIIB031 (rFVIIIFc)
9 Completed Assessment Of The Safety And Efficacy Of BG9924 In Rheumatoid Arthritis (RA) Patients
Condition: Rheumatoid Arthritis
Interventions: Biological: Placebo;   Biological: baminercept alfa;   Biological: Baminercept alfa
10 Recruiting A Study Evaluating the Effectiveness of Tecfidera™ (Dimethyl Fumarate) on Multiple Sclerosis (MS) Disease Activity and Patient-Reported Outcomes
Conditions: Relapsing-Remitting Multiple Sclerosis;   Multiple Sclerosis
Intervention: Drug: dimethyl fumarate (DMF)
11 Recruiting Ireland Natalizumab (TYSABRI®) Observational Program
Condition: Relapsing-Remitting Multiple Sclerosis
Intervention:
12 Completed ATP Expression in Lymphocytes of MS Patients by Means of "ImmuKnow®" Assay.
Condition: Multiple Sclerosis
Intervention:
13 Completed A Multicenter Study to Assess the Effect of Plasma Exchange in Accelerating the Clearance of Natalizumab in Subjects With Multiple Sclerosis (MS)
Condition: Relapsing Forms of Multiple Sclerosis
Interventions: Procedure: Plasma exchange;   Drug: natalizumab treatment
14 Completed
Has Results
Natalizumab (BG00002, Tysabri) Study in Japanese Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)
Condition: Multiple Sclerosis
Interventions: Drug: Natalizumab (BG00002);   Drug: Placebo
15 Active, not recruiting Extension Study to Evaluate Safety and Efficacy of BG00002 (Natalizumab) in Japanese Participants With Relapsing-Remitting Multiple Sclerosis
Conditions: Relapsing-Remitting Multiple Sclerosis;   Multiple Sclerosis
Intervention: Drug: BG00002 (natalizumab)
16 Completed JC-virus (JCV) Epidemiology in Multiple Sclerosis (MS)
Condition: Multiple Sclerosis
Intervention:
17 Completed 215ON201 BIIB033 In Acute Optic Neuritis (AON)
Condition: Acute Optic Neuritis
Interventions: Biological: BIIB033 (anti-LINGO-1 mAb);   Drug: Placebo
18 Completed Safety and Efficacy of Natalizumab (BG00002, Tysabri®) in Russian Participants With Relapsing Remitting Multiple Sclerosis (RRMS)
Condition: Relapsing-Remitting Multiple Sclerosis
Intervention: Biological: BG00002
19 Active, not recruiting BIIB017 (PEGylated Interferon Beta-1a) Related Flu-Like Symptoms in Relapsing Multiple Sclerosis Participants
Condition: Relapsing-Remitting Multiple Sclerosis
Interventions: Drug: BIIB017 (Peginterferon beta-1a);   Drug: Naproxen
20 Completed
Has Results
A Prospective, Open-label, Non-randomized, Clinical Trial to Determine if Natalizumab (Tysabri®) Improves Ambulatory Measures in Relapsing-remitting Multiple Sclerosis (RRMS) Patients
Condition: Relapsing Remitting Multiple Sclerosis (RRMS)
Intervention: Drug: BG00002 (natalizumab)

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years